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Abstract
Background and Objectives
Molecular data suggests that adiponectin may directly regulate urinary albumin excretion.
In the Diabetes Prevention Program (DPP) we measured adiponectin and albuminuria
before and after intervention, and we previously reported increases in adiponectin with inter-
ventions. Here we have used the DPP dataset to test the hypothesis that treatment-related
increases in adiponectin may reduce albuminuria in obesity.
Design, Setting, Participants and Methods
We evaluated cross-sectional correlations between plasma adiponectin and urinary albu-
min excretion at baseline, and the relationship of treatment-related changes in adiponectin
and albuminuria. Baseline and follow-up urine albumin to creatinine ratios (ACR (albumin to
creatinine ratio)) and plasma adiponectin concentration were available in 2553 subjects.
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Results
Adjusting for age, sex and race/ethnicity, we observed a statistically significant but weak
inverse relationship between adiponectin and ACR at baseline (conditional Spearman’s rho
= (-) 0.04, p = 0.04). Although DPP treatments significantly increased plasma adiponectin,
there were no treatment effects on ACR and no differences in ACR across treatment
groups. There was a weak direct (not inverse) association between change in adiponectin
and change in albuminuria (adjusted Spearman’s rho = (+) 0.04, p = 0.03).
Conclusions
In a large, well-characterized cohort of obese dysglycemic subjects we observed a weak
inverse association between circulating adiponectin concentrations and urinary albumin
excretion at baseline. Contrary to the hypothesized effect, treatment-related increases in
plasma adiponectin were not associated with a reduction in ACR. The association of change
in adiponectin with change in ACR should be assessed in populations with overt albuminuria
before excluding a beneficial effect of increasing adiponectin to reduce ACR in obesity.
Introduction
Adiponectin is an adipocyte-derived protein that circulates in high abundance. Paradoxically,
adiponectin concentrations are reduced with increasing obesity. Adiponectin can serve as a
marker of obesity-associated health risks [1–3]. Moreover, adiponectin appears to be function-
ally important in the vasculature [4, 5].
A direct role for adiponectin in the regulation of glomerular function has recently been sug-
gested. The adiponectin deficient mouse has increased urinary albumin excretion along with
other renal abnormalities [6], and in the glomerulus adiponectin deficiency induces segmental
fusion of foot processes, increased podocyte permeability, and albuminuria [7]. Therefore
reduced adiponectin concentrations (as commonly seen in obesity) may contribute to albumin-
uria, and conversely interventions that improve adiponectin levels may help reduce albuminuria.
The Diabetes Prevention Program (DPP) was a multicenter, randomized, placebo-controlled
clinical trial of the effect of intensive lifestyle modification or metformin versus placebo in the
prevention of diabetes onset among high risk subjects. The majority of this cohort had urine
albumin to creatinine ratios (ACR) below 30 mg/g [8]. In this cohort we have previously shown
a direct relationship between urine ACR and obesity (BMI (body mass index) in quartile 1 of
ACR 33±6, BMI in quartile 4 35±7; Spearman’s correlation coefficient 0.09, p<0.01) [8]. Sepa-
rately, we have also reported significant effects of DPP interventions to increase adiponectin
concentrations, which helped reduce diabetes incidence [1]. Here we have evaluated cross-sec-
tional associations of adiponectin and albuminuria at baseline in the DPP cohort, and tested the
hypothesis that treatment-related increases in adiponectin may reduce albuminuria in obesity.
Methods
The design, methodology and main outcomes of the DPP have been published previously [9].
In the DPP, subjects with elevated fasting glucose (5.3–6.9 mmol/L, or<6.9 mmol/L for Amer-
ican Indians), impaired glucose tolerance (glucose 7.8–11.0 mmol/L 2 hours after a 75 g oral
glucose load), and elevated body mass index (22 kg/m2 for Asian Americans,24 kg/m2 for
others) were randomly assigned to one of three treatments: intensive lifestyle intervention,
Adiponectin and ACR in the DPP
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treatment with metformin, or treatment with placebo [9]. An adaptive randomization method
stratified by study site was applied, to ensure balance of treatment assignments across centers
[10]. A fourth intervention arm using troglitazone was prematurely terminated; subjects from
that arm were not included in the present analyses. The majority of the cohort was obese
(mean BMI 34±7), and the cohort included approximately 55% of European descent, 20% Afri-
can American, 16% Hispanic American, 5% Native American, and 4% Asian American partici-
pants. All participants received standard advice for healthy diet and physical activity, including
recommendations to limit total caloric intake and to undertake regular physical exercise. Use
of thiazide diuretics or beta adrenergic antagonists was an exclusion criterion, but other classes
of antihypertensive agents were permitted. New medical therapies initiated by non-study phy-
sicians following enrollment were not restricted. Institutional Review Board approval was
obtained by each participating site (see S2 Appendix), and all participants included in this
report provided written informed consent for the main study and for subsequent investiga-
tions, including subsequent use of blood and urine samples for secondary analyses. The study
was performed in accordance with the Declaration of Helsinki.
All measurements were made on singly-thawed samples, using a study-wide central labora-
tory (Northwest Lipid Metabolism and Diabetes Research Labs, Seattle WA) for storage and
analyses. Urine samples were measured continuously as they arrived from study centers, using
a single automated methodology throughout the analysis period. Measurements were made on
blood samples collected following an overnight fast. Blood samples for adiponectin measures
were taken from long-term storage in 2006, and analyzed in batches with baseline and year 1
measurements from a given individual analyzed within a single measurement panel.
Total circulating adiponectin was measured in plasma using a latex-particle enhanced turbi-
dimetric assay (Otsuka Pharmaceutical, Tokyo). Details of the performance of this assay have
been previously published [11]; within-run and total coefficient of variation for this assay were
0.8–1.9% and 1.1–2.0%, respectively.
Urine albumin excretion (albuminuria) was assessed in DPP as a measure of the impact of
glycemia on kidney function. Singlet spot urine samples were collected at baseline and end-of-
study visits for measurement of albumin (Dade Behring BN II nephelometer) and creatinine
(Hitachi 917 autoanalyzer). Median follow-up time for the cohort used in our analysis is 3.1
(25th and 75th percentiles 2.5 and 3.8 years respectively), depending on timing of study entry
[9]. The albumin to creatinine ratio was calculated as the mathematical ratio of the urine con-
centrations of these analytes. Estimated glomerular filtration rate (eGFR) was calculated using
serum creatinine concentrations and the CKD-EPI (Chronic Kidney Disease Epidemiology
collaboration) equation [12, 13]. We applied the KDOQI 2012 guideline parameters for catego-
rizing degree of albuminuria [14], distinguishing values 30 mg/g (moderately severe albu-
minuria) from the normal range values below this threshold.
ACR and adiponectin exhibited skewed distributions, and the urine albumin concentrations
used in calculating ACR are truncated for values below the detection limit. Therefore we evalu-
ated unadjusted Spearman correlations, and conditional Spearman correlation coefficients
adjusting for demographic factors (age, race/ethnicity, and sex), which exhibit important asso-
ciations with adiponectin and/or ACR [1, 8]. Comparisons of variables across treatment groups
were performed with Chi-square test of independence for categorical variables, analysis of vari-
ance (ANOVA) for normal-distributed continuous variables or Kruskal-Wallace tests for
skewed ACR and adiponectin variables, testing whether distributions in the three groups were
different. For analyses by baseline adiponectin quartile, where rank ties at the quartile cut-
points occurred, tied observations were included in the upper category. Comparisons of the
baseline adiponectin distribution across different levels of the categorical variables were per-
formed using the Kruskal-Wallace test, and the relationship between baseline adiponectin and
Adiponectin and ACR in the DPP
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continuous variables were assessed using Spearman’s rank correlation coefficients. Compari-
sons of correlation coefficients across treatment groups were performed by applying a Fisher’s
z-transformation of the correlation coefficient values, constructing contrasts comparing each
transformed value to the mean of the transformed values from the three groups, and then eval-
uating whether these contrasts equal zero simultaneously. Quantile regression was used to per-
form multivariable analyses of determinants of change in ACR. Analyses were performed using
SAS 9.2 (SAS Institute, Cary NC).
Results
The total DPP cohort at randomization included 3234 participants in the three-arm random-
ized study [9]. ACR results were available in 3187 subjects at baseline (1064 lifestyle group sub-
jects, 1054 metformin group subjects, and 1069 placebo group subjects). Paired baseline and
end-of-study ACR measurements were available for 963 lifestyle subjects, 927 metformin sub-
jects, and 929 placebo subjects. Baseline adiponectin measurements were available for 3072
subjects (1028 lifestyle subjects, 1014 metformin subjects, and 1030 placebo subjects) and mea-
surements from samples taken at one year of treatment intervention were available in 2801
subjects (927 lifestyle subjects, 932 metformin subjects, and 942 placebo subjects). A total of
2553 participants had complete paired data (871 lifestyle, 837 metformin and 845 placebo
group individuals). The baseline characteristics (Table 1) of this majority subset of the overall
cohort did not differ from those of the complete cohort (not shown). All analyses presented
include only the subset with both sets of measurements.
Cross-sectional relationships of adiponectin and albuminuria
The distributions of baseline adiponectin concentrations and ACR in this population have
been separately published [1, 8]; for the subset analyzed the mean, median, 25th and 75th per-
centiles for adiponectin were 8.04, 7.4, 5.6 and 9.7 μg/mL and for ACR were 13.8, 5.5, 3.8 and
9.6 mg/g). ACR exhibited a strongly skewed distribution. 25% of participants had ACR above
10 mg/g (mildly increased albuminuria)[14]. Very few participants had ACR values above the
30 mg/g diagnostic threshold for moderately increased albuminuria and none of our partici-
pants had evidence of severely increased albuminuria. Analyses were not materially affected by
excluding participants with values above 30 (data not shown); analyses presented include these
participants. Urinary albumin concentrations were below the limit of detection in 13.5% (438/
3234) of subjects.
Table 2 presents clinical data and ACR values according to quartiles of adiponectin concen-
trations. At baseline, the unadjusted Spearman’s correlation coefficient between adiponectin
concentrations and ACR was (+)0.02 (p = 0.29; Table 2). Age, sex and race/ethnicity have
known relationships with adiponectin concentrations and with ACR in this cohort [1, 8];
adjusting for these potentially confounding variables produced a conditional Spearman corre-
lation coefficient of (-)0.04 (p = 0.04; Table 2).
The age/sex/race adjusted Spearman correlation coefficient between BMI and ACR was (+)
0.09 (p<0.001). Further adjusting for the contribution of adiponectin did not materially change
this relationship (r = (+)0.09, p<0.001). Similarly, adjusting the relationship of adiponectin
with ACR for the effect of BMI also did not materially change the relationship (r = (-)0.03,
p = 0.08). Obesity and circulating adiponectin concentrations therefore affect ACR indepen-
dent of one another in this cohort.
In view of a prior report of an inverse association between adiponectin concentration and
ACR specifically in an African American cohort [7], we undertook post-hoc analyses evaluat-
ing these relationships within race/ethnicity subgroups. These subgroups did not differ in their
Adiponectin and ACR in the DPP
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relationship between adiponectin and albuminuria (p = 0.48 comparing groups in unadjusted
analyses). Within each race/ethnicity subgroup the overall result was concordant with the
whole-cohort finding, reaching significance only among white participants (the largest single
subgroup, 1417 participants; adjusted r value (-)0.06, p = 0.02). The adjusted correlation coeffi-
cient among African American participants (477 participants) was (-)0.015, p = 0.74.
Women comprised about 2/3 of our study population and the overall study result was seen
among the women in our study (adjusted Spearman r value (-)0.06, p = 0.009). In the adjusted
analyses there was no significant sex difference in the relationship of adiponectin with ACR
(p = 0.09 comparing sexes).
These associations were evaluated within age subgroups (<45, 45–59,60 years), with no
significant associations evident within each age subgroup and no difference in the relationships
when comparing these groups (p = 0.77).
Baseline associations were present between blood pressure, ACR and adiponectin concen-
trations (Adiponectin versus DBP (diastolic blood pressure) r = (-)0.09, p<0.001; ACR versus
SBP (systolic blood pressure) r = (+)0.21, p<0.001; ACR versus DBP r = (+)0.12, p<0.001).
Table 1. Characteristics of the DPP cohort with evaluable adiponectin and albuminuria data at baseline and follow-up. The change in adiponectin
was calculated as Year 1 minus Baseline. The change in ACR was calculated as DPP-end minus baseline (see Methods). The p value is for comparisons of
each variable across the three treatment groups.
Lifestyle (n = 871) Metformin (n = 837) Placebo (n = 845) p value
Median [25th, 75th] orMean (SD) Median [25th, 75th] orMean (SD) Median [25th, 75th] orMean (SD)
Baseline
Sex (n, % of each group) 0.41
Male 293 (34%) 296 (35%) 273 (32%)
Female 578 (66%) 541 (65%) 572 (68%)
Race (n, % of each group) 0.32
Caucasian 485 (56%) 467 (56%) 465 (55%)
African American 149 (17%) 165 (20%) 163 (19%)
Hispanic 136 (16%) 133 (16%) 130 (15%0
Asian American 51 (6%) 26 (3%) 37 (4%)
Native American 50 (6%) 46 (5%) 50 (6%)
Age (yrs) 51.7 (11.1) 51.8 (10.0) 51.1 (10.1) 0.18
BMI (kg/m2) 33.5 (6.5) 33.7 (6.4) 34.1 (6.7) 0.04
Waist (cm) 105 (14) 105 (14) 105 (14) 0.33
HOMA-IR (U) 6.8 (3.9) 7.1 (4.1) 7.1 (4.3) 0.15
2hr OGTT glucose (mg/dL) 164 (17) 165 (17) 165 (17) 0.51
Serum Creatinine (mg/dL) 0.8 (0.2) 0.8 (0.2) 0.8 (0.2) 0.45
eGFR (ml/min/1.73 m2) 97.1 (16.6) 97.2 (16.3) 97.9 (16.4) 0.27
Adiponectin (μg/mL) 7.50 [3.63, 8.12] 7.40 [3.61, 8.16] 7.20 [3.32, 7.83] 0.20
ACR (mg/g) 5.45 [14.65, 54.06] 5.43 [13.80, 35.02] 5.57 [12.92, 58.60] 0.69
Post-Treatment Results
Adiponectin (μg/mL) 8.30 [3.94, 8.93] 7.40 [3.61, 8.16] 7.20 [3.32, 7.83] <0.001
ACR (mg/g) 5.78 [14.79, 85.44] 5.61 [14.04, 38.73] 5.61 [14.97, 47.61] 0.72
Change During DPP
Adiponectin (μg/mL) 0.81 [0.60, 1.72] 0.20 [0.10, 1.45] 0.10 [0.00, 1.24] <.0001
ACR (mg/g) 0.14 [0.07, 97.57] 0.24 [0.07, 37.34] 2.05 [0.17, 46.43] 0.52
ACR, albumin to creatinine ratio; BMI, body mass index; eGFR, estimated glomerular ﬁltration rate; HOMA-IR, homeostasis model assessment of insulin
resistance; OGTT, oral glucose tolerance test.
doi:10.1371/journal.pone.0136853.t001
Adiponectin and ACR in the DPP
PLOSONE | DOI:10.1371/journal.pone.0136853 August 27, 2015 5 / 11
Adding adjustment for DBP to the age/sex/race adjusted model did not materially change the
apparent relationship between adiponectin and ACR (Spearman’s r = (-)0.04, p = 0.04).
At baseline, self-reported use of angiotensin converting enzyme inhibitors (ACEI) or angio-
tensin receptor blockers (ARB) was associated with ACR (r = (+)0.06, p = 0.004). However,
there was no relationship of ACEI or ARB use with adiponectin concentrations. Therefore we
did not adjust the above analyses for use of these medications
Effects of Intervention-related changes in adiponectin on albuminuria
At study baseline, there were no differences across treatment groups in ACR or prevalence of
moderately severe albuminuria (previously denoted ‘microalbuminuria’) [14], with a study-
wide prevalence of 6.4%. At the end of the study, the prevalence of moderately severe albumin-
uria (ACR 30 mg/g) was 7.0%, 6.5%, and 5.6% in placebo, metformin, and lifestyle groups
respectively (p = 0.51 comparing treatment groups). Median ACR values did not differ across
groups at end of study (5.8, 5.6, and 5.6 mg/g for placebo, metformin, and lifestyle, p = 0.72).
There was no significant change in ACR with intervention within the DPP, and change in ACR
was not significantly different across treatment groups (Table 1).
The magnitudes of change in adiponectin and ACR are reported in Table 1; the change in
adiponectin differed across treatment groups but the change in ACR did not (as we have
Table 2. Relationships of albuminuria, renal function, andmetabolic variables with adiponectin concentrations at baseline. All variables are pre-
sented as mean (SD) except as noted for ACR, which is highly skewed. Spearman’s correlations are presented for continuous variables versus baseline adi-
ponectin levels. For categorical variables such as race and sex, the distributions of adiponectin within each category were compared using the Kruskal-
Wallace test (denoted by *). Results are presented for unadjusted correlations, and following adjustment for race/ethnicity, sex and age. The numbers of indi-
viduals in each quartile are unequal due to ties, which are included in the higher quartile.
Adiponectin Quartile
1 2 3 4 Unadjusted (p value) Adjusted (p value)
N 625 650 625 653
Adiponectin (μg/mL) 4.5 (0.8) 6.5 (0.5) 8.4 (0.7) 12.7 (3.3) - -
Sex <0.001
Male 321 (51%) 197 (38%) 172 (28%) 119 (18%)
Female 304 (49%) 400 (62%) 453 (72%) 534 (82%) -
Race (n, % of each quartile) <0.001* -
Caucasian 257 (41%) 359 (55%) 360 (58%) 441 (68%)
African American 191 (31%) 115 (18%) 95 (15%) 76 (12%)
Hispanic 100 (16%) 100 (15%) 103 (16%) 96 (15%)
Asian American 43 (7%) 36 (6%) 28 (4%) 7 (1%)
Native America 34 (5%) 40 (6%) 39 (6%) 33 (5%)
Age 48.4 (9.7) 49.8 (10.2) 52.1 (10.3) 55.7 (9.9) 0.28 (<0.001) -
BMI (kg/m2) 34 (6) 34 (7) 34 (6) 33 (6) -0.07 (0.0003) -0.08 (0.0002)
Waist (cm) 107 (14) 107 (15) 105 (14) 101 (13) -0.16 (<0.0001) -0.11 (<0.0001)
HOMA-IR (U) 9 (5) 7 (4) 7 (4) 5 (3) -0.34 (<0.0001) -0.31 (<0.0001)
2hr OGTT glucose (mg/dL) 165 (17) 165 (17) 165 (17) 164 (17) -0.03 (0.19) -0.05 (0.019)
eGFR (mL/min/1.73m2) 101 (17) 99 (16) 97 (16) 93(16) -0.19 (<0.0001) -0.02 (0.29)
Serum Creatinine (mg/dL) 0.82 (0.18) 0.79 (0.18) 0.77 (0.17) 0.76 (0.16) -0.14 (<0.0001) 0.01 (0.52)
ACR (mg/g) 5.40 [3.55, 10.59] 5.39 [3.79, 9.47] 5.52 [3.79, 9.03] 5.69 [3.85, 9.83] 0.02 (0.29) -0.04 (0.04)
(Median [25th, 75th])
ACR, albumin to creatinine ratio; BMI, body mass index; eGFR, glomerular ﬁltration rate estimated using the CKD-EPI equation; HOMA-IR, homeostasis
model assessment index of insulin resistance; OGTT, oral glucose tolerance test.
doi:10.1371/journal.pone.0136853.t002
Adiponectin and ACR in the DPP
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previously reported for each finding individually [1, 15]). The central hypothesis for the cur-
rent analyses is that treatment-related increases in adiponectin may reduce albuminuria in obe-
sity. We therefore evaluated whether the change in adiponectin was associated with change in
ACR (Table 3). All correlation coefficients were positive, indicating concordant (not inverse)
changes in ACR and adiponectin; these correlations were not statistically significant within
treatment groups, but did achieve significance when all treatment groups were pooled. The
magnitude of this association was small. The the coefficients and significance were unaffected
by adjustments for age, race, and sex. In exploratory quartile regression analyses, we found that
lower baseline ACR, greater change in DBP and female sex were significantly associated with
increase in ACR; specifically, baseline adiponectin, change in adiponectin, baseline BMI, race/
ethnicity and baseline use of angiotensin converting enzyme inhibitor were not significantly
related to change in ACR in these analyses.
Discussion
Recent reports of direct functional effects of adiponectin on podocyte function suggest that
interventions that augment adiponectin concentrations might help reduce albuminuria. In this
context, we have evaluated the relationships between circulating adiponectin concentration
and urinary albumin to creatinine ratio (ACR) at baseline, and the changes in these variables
with study interventions, among more than 2500 obese normo-albuminuric participants in the
Diabetes Prevention Program. In this large, well validated cohort we found a statistically signif-
icant but weak inverse relationship between adiponectin and ACR at baseline. Despite benefi-
cial effects of DPP treatments to increase adiponectin, there was no evidence for a treatment
effect on albuminuria and no evidence for an inverse relationship between treatment-induced
change in adiponectin and change in albuminuria. To the contrary, we observed a statistically
significant direct correlation of change in adiponectin with change in ACR, arguing strongly
against an effect of increased adiponectin to reduce albuminuria in this population.
Cross-Sectional Relationships
The epidemiologic association between circulating adiponectin concentrations and measures
of urinary protein excretion differs according to different stages of renal disease [6, 16–21].
Within low-albuminuric populations with dysglycemia the data are inconsistent. Most groups
have observed an inverse relationship as we have seen here [7, 22–26], but the literature also
includes reports of absent or even direct relationships [18, 27, 28]. A recent publication evalu-
ated associations of molecular weight isoforms of adiponectin with albuminuria in a normo-
albuminuric non-obese European white population, and found direct (not inverse) relation-
ships of high molecular weight adiponectin with ACR, although with a very modest slope [28].
In that report, other isoforms were not significantly associated with ACR. The FinnDiane
Study Group [18] describes comparable adiponectin concentrations in the moderately severe
(micro)-albuminuric group (12.1±5.8 mg/dL) versus the normo-albuminuric group (12.3±6.2),
both lower than the severely albuminuric group (18.1±12.0). Similar patterns are evident in
other reports in subjects with diabetes [16, 17]. Although the coefficients for these associations
were not formally reported for each subgroup, there do not appear to be differences in circulat-
ing adiponectin concentrations between normo-albuminuric and moderately albuminuric sub-
ject groups in these reports. In a cohort of 440 obese people of European descent, 80% women,
the correlation between adiponectin and ACR was (-)0.26, concordant with our current obser-
vations. By virtue of the design of the DPP, we have data from a large, well-defined obese dys-
glycemic (but non-diabetic) population. Our observation of a weakly inverse but statistically
significant cross-sectional relationship is consistent with prior observations of inverse
Adiponectin and ACR in the DPP
PLOSONE | DOI:10.1371/journal.pone.0136853 August 27, 2015 7 / 11
relationships, and our large sample size provides confidence in the precision of the estimate.
However, this association is weak and therefore the relationship between low adiponectin and
urinary albumin excretion is of questionable physiologic and epidemiologic relevance, at least
in obese populations with normo-albuminuria.
Treatment-Induced Changes
The assessment of inter-relationships of change in these variables with DPP interventions is
more informative in terms of evaluating physiologic interactions between adiponectin and albu-
minuria. There is good reason to expect that change in adiponectin will directly affect albumin-
uria: Whole-animal genetic deficiency of adiponectin is associated with albuminuria and
multiple renal abnormalities [6]; adiponectin was recently shown to be directly involved in
podocyte structure and function in an in vitro model [7]; and adiponectin overexpression/
underexpression directly affects renal response to a genetically induced renal injury [29]. Also,
low baseline adiponectin concentrations were predictive of progression of albuminuria in a T2D
cohort with elevated baseline albuminuria [30]. In the DPP, all 3 treatment interventions (pla-
cebo, metformin, lifestyle) were associated with increases in circulating adiponectin and these
changes were proportional to weight loss and to the diabetes prevention effects of the interven-
tions (1). Despite these treatment-induced changes in adiponectin concentration, we found no
differences in albumin excretion by treatment group, and we found no evidence for an inverse
relationship between change in adiponectin and change in albuminuria. In fact, we observed a
statistically significant direct (not inverse) correlation between changes in these parameters.
Surgically-induced weight loss can reduce urinary albumin excretion in obese diabetic sub-
jects [31]; it is possible that this effect of weight loss is mediated by adiponectin. However, the
DPP interventions did not produce any measurable reduction in albuminuria despite signifi-
cant weight loss and the attendant increases in circulating adiponectin. The antidiabetic agents
rosiglitazone (a PPARgamma agonist) and miglitol (an alpha-glucosidase inhibitor) have been
found to concordantly improve adiponectin and urinary albumin excretion [32, 33], and it is
possible that these observations reflect beneficial actions of adiponectin on albuminuria. The
current observations suggest that treatment-induced changes in adiponectin cannot be
expected to reduce albuminuria within the normo-albuminuric range. Further studies specifi-
cally evaluating treatment-induced changes in adiponectin with treatment effects on albumin
excretion in populations with at least moderately severe albuminuria will be needed to under-
stand whether the relationships predicted from molecular studies are important in states with
more overtly abnormal albuminuria.
Strengths and Limitations
Two main strengths of our study are noteworthy. First, we studied the relationships of adipo-
nectin and albuminuria in the largest cohort of normo-albuminuric subjects reported to date.
Second, our cohort is multi-ethnic and therefore broadly representative.
Table 3. Correlations of Changes in Adiponectin and Changes in Albumin/creatinine ration (ACR). Adiponectin concentrations were measured at
baseline and at Year 1 of intervention. ACR was measured at baseline and at end-of-study. Values presented are Spearman’s correlation coefficient ρ (p
value), except the column testing group differences in the correlation. Adjustments include age, race and sex.
Lifestyleρ (p value)
N = 871
Metforminρ (p value)
N = 837
Placeboρ (p value)
N = 845
p value comparing
groups
Pooled correlationρ (p value)
N = 2553
Unadjusted 0.06 (0.09) 0.05 (0.16) 0.02 (0.50) 0.77 0.04 (0.03)
Adjusted 0.06 (0.09) 0.05 (0.14) 0.02 (0.56) 0.71 0.04 (0.03)
doi:10.1371/journal.pone.0136853.t003
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Limitations also apply. Urine ACR values were measured in single, random spot urines;
future studies with repeated timed urines may provide additional insights. Nevertheless, our
observations are consistent with recent reports of inverse associations in non-obese normo-
albuminuric populations [26, 28]. Since our study population was normo-albuminuric, failure
to improve albuminuria from this already low range is perhaps not surprising; observations in
this type of population have not been previously reported. The current findings may not reflect
the relationship among populations with greater degrees of albuminuria.
Summary
In a large, well-characterized cohort of obese dysglycemic subjects at risk for diabetes we found
evidence for a statistically significant but weak inverse association between circulating adipo-
nectin concentrations and urinary albumin excretion, measured as the albumin to creatinine
ratio (ACR). DPP treatment interventions produced significant increases in circulating adipo-
nectin, but these treatments were not associated with a significant change in ACR, and there
was no evidence for treatment-induced increases in adiponectin to drive reductions in albu-
minuria. Further studies evaluating the effects of treatment-induced improvements in adipo-
nectin and albuminuria are needed, in populations with manifest albuminuria.
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